Dean Connolly is impressed by a recent systematic review and network meta-analysis, which compares the efficacy and tolerability of medication for ADHD in children, young people and adults.
[read the full story...]
Derek Tracy takes a first look at the Novel Psychoactive Substances in the UK Project; an NIHR-funded empirical and conceptual review that recommends research priorities in the field.
[read the full story...]
Harry Sumnall, Ian Hamilton and Mark Monaghan provide an overview of Novel Psychoactive Substances (NPS) aimed at health professionals and others who work with people who use these new psychoactive substances.
[read the full story...]
Samuele Cortese considers the findings of a recent nationwide self controlled case series study of the cardiovascular safety of methylphenidate use in children and young people with ADHD.
[read the full story...]
Samuele Cortese publishes his debut Mental Elf blog on a meta-analysis of n-of-1 trials, which shows that amphetamine derivatives and methylphenidate are superior to placebo, in the short term, for paediatric ADHD.
[read the full story...]
Chris Hollis appraises a recent Cochrane systematic review, which casts doubt over the quality of trial evidence and the clinical effectiveness of Methylphenidate for ADHD.
[read the full story...]
John Baker summarises a review of commonly prescribed medication that covers seven psychiatric drugs, including antidepressants, antipsychotics, benzodiazepines, amphetamines, methylphenidate and cholinesterase inhibitors.
[read the full story...]
Joff Jones highlights an important public health finding from a recent prospective cohort study about the effect of stimulant drugs on the risk of injuries in children with ADHD.
[read the full story...]
Lisa Burscheidt summarises a recent randomised controlled trial of combined methylphenidate and citalopram for depression in older people, which presents promising but limited findings.
[read the full story...]
A new study finds that psychiatric medications are implicated in many adverse drug events treated in US emergency departments. Nearly 1 in 10 of all adverse drug event visits to emergency departments are due to psychiatric drugs, including antidepressants, antipsychotics, lithium salts, sedatives, anxiolytics and stimulants.
[read the full story...]
